T he original Navas-Acien et al article 1 and their subsequent commentary 2 do not provide valid evidence of an association between low levels of arsenic exposure and diabetes. The reported odds ratios near 2.0 -4.0 are inconsistent with those near one we obtained, and result from errors in multiple regression analyses (including inappropriate adjustments for arsenobetaine and creatinine).
variation possibly due to urine dilution. In addition, arsenic and creatinine concentrations in urine have been found to be correlated, even after adjusting for urine dilution measured by specific gravity. 4 Other evidence also suggests that differences in urine creatinine levels between patients with diabetes and nondiabetics are not due to urine volume. 6 Because of all these factors, adjusting for creatinine to account for urine dilution can distort results. We found this in our analyses. When we adjusted for creatinine, some people with very low arsenic concentrations (ie, Ͻ1.6 g/L) ended up in the highest quintile of arsenic exposure. Because of small sample size, even small changes in the numbers of patients with diabetes in each exposure category can have profound effects on odds ratio estimates.
Further evidence of this distortion comes from the fact that the high odds ratios reported by Navas-Acien et al occur only when creatinine is entered as a continuous variable. One method of dealing with the over-dispersion in creatinine is to divide creatinine into quartiles so that outliers are merely in the appropriate quartile. When we enter creatinine as a categorical variable (ie, indicator variables for each quartile of creatinine concentration), the odds ratio for high arsenic becomes 1.19 (0.10 -14.0) (Table) . One might expect small changes in the odds ratios following adjustment for urine dilution, or small changes when entering creatinine as a categorical rather than as a continuous variable. However, the very large changes reported by Navas-Acien et al are a statistical artifact.
In his commentary, Matthew Longnecker suggests that the odds ratios near 1.0 that we reported could be due to negative confounding by dimethylarsinate (DMA) from seafood. 7 However, the degree of confounding needed to change an odds ratio near 4.0 to an odds ratio near 1.0 would have to be extraordinarily large. In addition, since most ingested inorganic arsenic is metabolized to DMA, there is already DMA in urine from inorganic arsenic exposure. DMA is known to be toxic. The idea that some additional DMA from fish (or arsenosugar) protects one from diabetes, and causes confounding strong enough to completely mask the odds ratios near 3.0 -4.0 reported by Navas-Acien et al, is not plausible.
The odds ratios near 1.0 we report for diabetes with very low (ie, background) levels of arsenic in NHANES are consistent with previous studies showing only modestly increased relative risks at exposure levels up to around 50 times higher than seen in NHANES. 3 Our findings highlight the importance of biologic plausibility and the need for caution in conducting multiple regression modeling. Contrary to the statements of Navas-Acien et al, there is no evidence that persons with low arsenic exposure in the United States are at increased risk of diabetes. 
